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Abstract
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse
reactions associated with fatal disorders. Although many causes of SJS/TEN have been proposed, the time-to-onset
for SJS/TEN and the relationship between aging and SJS/TEN are still not clear. Therefore, the aim of this study was
to determine the relationship between aging and SJS/TEN using the Japanese Adverse Drug Event Report (JADER)
database and analyze the time-to-onset profile of SJS/TEN.
Methods: We analyzed reports of SJS/TEN recorded in the JADER database between 2004 and 2015 using an
adjusted reporting odds ratio (ROR). We also used Weibull proportional hazards models for each drug to examine
the expression patterns of SJS/TEN. We selected the drugs according to the number of the reports associated with
SJS/TEN.
Results: The JADER contained 330,686 reports from April 2004 to April 2015. The adjusted RORs for patients in the
0–19-, 20–39-, 60–79-, and ≥ 80-year-old groups from all data extracted from the JADER database were 1.33 (95 %
confidence interval [CI], 1.21–1.45), 1.78 (95 % CI, 1.65–1.93), 0.71 (95 % CI, 0.66–0.75), and 0.72 (95 % CI, 0.66–0.79),
respectively. The adjusted ROR tended to be higher in patients aged 0–19 years, particularly in patients using
antipyretic analgesics, such as loxoprofen or acetaminophen. More than half of the cases of SJS/TEN onset
following administration of loxoprofen and acetaminophen occurred within 4 days of the initiation of treatment.
The median times-to-onset were 3 days for loxoprofen and 2 days for acetaminophen. The scale parameter α
values of loxoprofen and acetaminophen were 9.44 and 6.17, respectively. The upper 95 % CIs of shape parameter
β values for the drugs were all less than 1, with the exceptions of those for carbamazepine, ACE inhibitors, and
corticosteroids.
Conclusions: Our results suggested that monitoring of younger patients who frequently use antipyretic analgesics
is important. These drugs should be used and monitored within the first 2–3 days of treatment in the Japanese
population.
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Background
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are severe mucocutaneous blistering
disorders [1]. SJS and TEN have a significant impact on
public health because of their associated high mortality
rates (1–10 % for SJS and 20–40 % for TEN) [1–3].
Although the pathogenesis of SJS/TEN is not fully
understood, these disorders are thought to be related to
dysfunctions of the immune system. Moreover, the oc-
currence of SJS/TEN is usually associated with hypersen-
sitivity to medications [4–6].
The incidences of SJS and TEN are estimated to range
from 1 to 6 and 1 to 3 cases per million person-years,
respectively [1, 2, 7, 8]. Since SJS and TEN are very rare
diseases, evaluation of the relationship between sus-
pected medication and SJS/TEN onset is difficult. Gener-
ally, spontaneous reporting systems (SRSs) are useful for
the detection of new, rare, and severe adverse events.
We have already analyzed reports of SJS/TEN using the
United States (U. S.) Food and Drug Administration
(FDA) Adverse Events Reporting System (FAERS) and
have demonstrated a relatively high value for the signal
(reporting odds ratio [ROR]) of SJS/TEN in patients ages
17 years and younger [9].
The genetic features of human leukocyte antigen in in-
dividuals may affect the incidence of SJS/TEN [10]. As
such, regional differences in drug prescriptions should
be taken into account. In the Japanese population, the
incidence of SJS/TEN and the relationship between
aging and SJS/TEN have still not been assessed. The
regulatory authority of Japan, i.e., the Pharmaceuticals
and Medical Devices Agency (PMDA), has released an
SRS of the Japanese Adverse Drug Event Report (JADER)
database. The JADER database is the best-known database
in Japan and is one of the primary tools used for pharma-
covigilance [11]. Indexes for signal detection, such as
ROR, have been developed for use in the SRS to iden-
tify drug-associated adverse events by disproportional-
ity analysis [12–14].
The European SCAR Study (EuroSCAR Study) is an
international multicenter case–control study designed
for surveillance of medication risks for SJS/TEN [6].
Time latency between the beginning of drug use and the
onset of adverse events has been demonstrated in the
EuroSCAR Study [6]. Accordingly, analysis of time-to-
onset has recently been proposed as a method to detect
signals for adverse events in the SRS. The rate of occur-
rence of adverse events after prescription is thought to
depend on the causal mechanism and will often vary
over time; in contrast, adverse events not associated with
the drug will occur at a constant background rate.
Therefore, varying rates of adverse events over time may
indicate a drug-event relationship. The Weibull shape
parameter (WSP) test is used for the statistical analysis
of time-to-onset data and can describe the varying inci-
dence of adverse events (i.e., changes in risk over time).
Additionally, time-to-onset analysis with WSP has been
used to evaluate hazard functions for detecting adverse
events.
In this study, we evaluated the relationship between
aging and SJS/TEN using RORs adjusted by logistic re-
gression analyses in the JADER database and compared
these results with previous results obtained from the
FAERS database. We also applied time-to-onset analysis
using WSP tests to the evaluation of SJS/TEN reports.
To the best of our knowledge, this study is the first to
evaluate time-to-onset data for SJS/TEN using the SRS.
Methods
Data sources
Data from the JADER database, which has been used to
record data from April 2004 to April 2015, were ob-
tained from the PMDA website (www.pmda.go.jp). The
structure of the JADER database complies with the
international safety reporting guidelines (ICH E2B). The
database consists of four data Table 1) patient demo-
graphics information (demo), 2) drug information (drug),
3) adverse events (reac), and 4) primary illness (hist).
The JADER database does not contain the code for iden-
tification of case reports (A1.11); therefore, we did not
perform data cleaning. The “Drug” file (drug informa-
tion) contains the role code assigned to each drug: sus-
pected drug (“higiyaku” in Japanese), interacting drug
(“sougosayou” in Japanese), and concomitant drug
(“heiyouyaku” in Japanese). In this study, we analyzed re-
cords of suspected drugs.
Definition of adverse events
According to the terminology preferred by the Medical
Dictionary for Regulatory Activities (MedDRA) version
17.1 [15], which were coded in “reac” table, we extracted
case reports of SJS/TEN. We used the following three
preferred terms (PT) to match SJS and TEN: SJS/
PT10042033, oculomucocutaneous syndrome/PT10030081,
and TEN/PT10044223. We excluded the reports that were
uncompleted with age or sex information.
Signal detection
The PMDA and Netherlands Pharmacovigilance Center
use the ROR to detect the signal of adverse events from
the SRS [16]. The ROR was calculated from two-by-two
contingency tables of the presence or absence of a par-
ticular drug and a particular adverse event in the case
reports. The ROR is the ratio of the odds of reporting
adverse events versus all other events associated with
the drug of interest compared with the reporting odds
for all other drugs present in the database [16]. Use of
the ROR allows for adjustment through logistic
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Table 1 SJS/TEN in the Japanese Adverse Drug Event Report database (April 2004–April 2015)

























Total 6568 353988 1.86 544 2642 20.59 525 4714 11.14 498 1925 25.87 420 4517 9.30 403 2375 16.97
Stratified by agea
≤19 years M 388 12982 2.99 1 9 11.11 14 69 20.29 87 325 26.77 35 345 10.14 3 76 3.95
F 295 12088 2.44 0 7 0.00 12 80 15.00 83 262 31.68 17 265 6.42 17 144 11.81
20-39 years M 470 13842 3.40 22 98 22.45 89 368 24.18 32 129 24.81 41 369 11.11 32 191 16.75
F 791 20302 3.90 11 39 28.21 100 555 18.02 101 298 33.89 54 481 11.23 82 554 14.80
40-59 years M 723 36749 1.97 80 454 17.62 60 606 9.90 33 155 21.29 40 630 6.35 60 318 18.87
F 796 36347 2.19 39 126 30.95 90 631 14.26 58 205 28.29 49 495 9.90 76 331 22.96
60-79 years M 1192 86098 1.38 154 902 17.07 88 991 8.88 45 218 20.64 77 761 10.12 25 170 14.71
F 1099 71275 1.54 106 420 25.24 53 889 5.96 45 198 22.73 76 569 13.36 53 251 21.12
≥80 years M 227 18393 1.23 35 218 16.06 6 169 3.55 3 39 7.69 5 121 4.13 10 27 37.04
F 383 22610 1.69 89 266 33.46 9 300 3.00 8 66 12.12 10 153 6.54 6 39 15.38
Subtotal 6364 330686 1.92 537 2539 21.15 521 4658 11.19 495 1895 26.12 404 4189 9.64 364 2101 17.33
















regression analysis and offers the advantage of control-
ling for covariates [17].
In this analysis, we selected the drugs based on the
quantity of reports and refined the results with a dedi-
cated correction to detect possible confounders present
in the database [17]. We calculated adjusted RORs for
control of covariates, using logistic regression analysis.
The reports were stratified by age as follows: ≤19 years,
20–39 years, 40–59 years, 60–79 years, and ≥80 years.
To construct the logistic model, gender, reporting year,
and stratified age groups were coded. In this study, we
defined the youngest group as less than 20 years old, un-
like in our previous research, because age is recorded in
10-year intervals in the JADER database. The following
logistic model was used for analysis:
Log oddsð Þ ¼ β0 þ β1Y þ β2G þ β3A
where Y is the reporting year, G is gender, and A is the
stratified age group.
For signal detection, general qualitative judgments
were used. The detection of a signal was dependent on
the signal indices exceeding a predefined threshold. ROR
values of less than 1 indicated no potential exposure-event
associations, and estimates of more than 1 indicated po-
tential exposure-event safety signals. The safety signals
were considered significant when the ROR estimates and
the lower limits of the corresponding 95 % confidence
interval (CI) were greater than or equal to 1 [16].
The adjusted RORs were calculated using the 40–59-
year-old group as a reference group. A likelihood ratio
test was used to evaluate the effects of explanatory
variables. A probability (p) value of 0.05 or less was
considered statistically significant because the difference
in −2 log likelihood followed a chi-square distribution
with one degree of freedom.
Time-to-onset analysis
Time-to-onset duration from the JADER database was
calculated from the time of the patient’s first prescrip-
tion to the occurrence of the adverse events. The median
duration, quartiles, and WSPs were used to evaluate the
time-to-onset data [18].
The scale parameter α of the Weibull distribution de-
termines the scale of the distribution function. A larger
scale value (α) stretches the distribution, while a smaller
scale value shrinks the data distribution. The shape par-
ameter β of the Weibull distribution determines the
shape of the distribution function. A larger shape value
gives a left-skewed curve, whereas a smaller shape values
gives a right-skewed curve. In the analysis of the SRS,
the shape parameter β of the Weibull distribution was
used to indicate the hazard without a reference popula-
tion as follows. When β was equal to 1, the hazard was
estimated to be constant over time. If β was greater than 1
and the 95 % CI of β excluded the value 1, the hazard was
considered to increase over time. Finally, if β was less than
1 and the 95 % CI of β excluded the value 1, the hazard
was considered to decrease over time [19, 20].
Data analyses were performed using JMP, version 11.0
(SAS Institute Inc., Cary, NC, USA).
Results
The JADER contained 353,988 reports from April 2004
to April 2015. After extracting reports having complete
gender and age information, 330,686 reports remained;
these reports were used for the analysis. The numbers of
reports obtained for each PT were 3,653 for SJS, 841 for
oculomucocutaneous syndrome, and 2,183 for TEN. The
numbers of cases and reporting ratios for allopurinol,
loxoprofen, acetaminophen, carbamazepine, and lamo-
trigine were 544 (20.6 %), 525 (11.1 %), 498 (25.9 %),
420 (9.3 %), and 403 (17.0 %), respectively. Data de-
scribing these top five most frequent drugs are sum-
marized in Table 1. The number of reported cases for
the 60–79-year-old group was 2,291; this was the
highest value among all age-stratified groups.
The adjusted RORs and 95 % CIs for the whole
data and subset data are summarized in Table 2. The
adjusted RORs for patients in the 0–19-, 20–39-, 60–79-,
and ≥ 80-year-old groups from all data extracted from the
JADER database were 1.33 (95 % CI, 1.21–1.45), 1.78
(95 % CI, 1.65–1.93), 0.71 (95 % CI, 0.66–0.75), and 0.72
(95 % CI, 0.66–0.79), respectively. A likelihood ratio test
was used to evaluate the effects of adding the term of
stratified age for adverse events. Adding the age term for
0–19-, 20–39-, 60–79-, and ≥ 80-year-old groups, i.e.,
for all age groups, had statistically significant effects
(p < 0.0001). The estimated values for the 0–19- and
20–39-year-old groups in the logistic regression
exceeded 0 (estimated beta [β3] for 0–19-year-old
group was 0.284, and that for the 20–39-year-old
group was 0.579). Furthermore, we calculated the ad-
justed RORs for allopurinol, loxoprofen, acetamino-
phen, carbamazepine, and lamotrigine using the
subset analysis. When considering the subset data for
loxoprofen, the adjusted RORs for loxoprofen in pa-
tients in the 0–19-, 20–39-, 60–79-, and ≥ 80-year-old
groups were 1.54 (95 % CI, 0.96–2.39), 1.89 (95 % CI,
1.49–2.39), 0.59 (95 % CI, 0.46–0.75), and 0.25 (95 %
CI, 0.14–0.41), respectively. The likelihood ratio tests
for the age terms of 20–39-, 60–79-, and ≥ 80-year-old
groups had statistically significant effects (p < 0.0001). The
adjusted RORs tended to be higher in the 20–39-year-old
group. In contrast, the effect of the age term of the 0–19-
year-old group was not statistically significant according
to the likelihood ratio test (p = 0.0751). For acetamino-
phen, the adjusted RORs in patients in the 0–19-, 20–39-,
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60–79-, and ≥ 80-year-old groups were 1.26 (95 % CI,
0.94–1.70), 1.31 (95 % CI, 0.95–1.79), 0.83 (95 % CI,
0.60–1.16), and 0.33 (95 % CI, 0.16–0.62), respect-
ively. The likelihood ratio tests for the age term of
the ≥ 80-year-old group showed statistically significant
effects (p = 0.0004); however, the effects of the age
terms of the 0–19-, 20–39-, and 60–79-year-old
groups for acetaminophen were not statistically sig-
nificant (p = 0.1292, p = 0.0972, and p = 0.2818, re-
spectively). For carbamazepine, the adjusted RORs in
patients in the 0–19-, 20–39-, 60–79-, and ≥ 80-year-
old groups were 1.09 (95 % CI, 0.76–1.55), 1.43 (95 %
CI, 1.06–1.95), 1.52 (95 % CI, 1.15–2.00), and 0.66
(95 % CI, 0.36–1.12), respectively. The effects of the
age term of the 20–39- and 60–79-year-old group in
the likelihood test (p = 0.0209, and p = 0.0027, respect-
ively) in the subset data of carbamazepine were statis-
tically significant, and the adjusted ROR was elevated
in 20–39- and 60–79-year-old groups for carbamaze-
pine. The effects of the age terms in the 20–39- and
60–79-year-old groups were statistically significant.
For allopurinol, the effects of term in any age group
were not statistically significant. For lamotrigine, the ad-
justed RORs were low in the 0–19- and 20–39-year-old
groups.
For the time-to-onset analysis, the JADER database
contained 2,575,326 combinations of drugs and adverse
drug reactions (ADRs). After extracting the combinations
having complete information for the date of starting treat-
ment and the date of adverse event onset, 2,337,656 com-
binations were analyzed. A total of 21,502 events were
identified for all drugs associated with SJS/TEN. From
these, we analyzed the top five most frequently listed
drugs, i.e., allopurinol, loxoprofen, acetaminophen, carba-
mazepine, and lamotrigine (Table 1). We also evaluated









Reporting Year −0.025 <0.0001b 0.98 (0.97-0.98)
Gender female 0.104 <0.0001b 1.11 (1.06-1.17)
Age
≤ 19 years 0.284 <0.0001b 1.33 (1.21-1.45)
20-39 years 0.579 <0.0001b 1.78 (1.65-1.93)
40–59 yearsa
60–79 years −0.349 <0.0001b 0.71 (0.66-0.75)
≥ 80 years −0.327 <0.0001b 0.72 (0.66-0.79)
Allopurinol
Reporting Year 0.005 0.7756 1.00 (0.97-1.04)
Gender female 0.630 <0.0001b 1.88 (1.54-2.29)
Age
≤ 19 years −1.515 0.0713 0.22 (0.01-1.11)
20-39 years 0.165 0.4712 1.18 (0.75-1.82)
40–59 yearsa
60–79 years −0.123 0.3285 0.88 (0.69-1.13)
≥ 80 years 0.073 0.6324 1.08 (0.80-1.45)
Loxoprofen
Reporting Year −0.027 0.0706 0.97 (0.95-1.00)
Gender female −0.150 0.1154 0.86 (0.71-1.04)
Age
≤ 19 years 0.429 0.0751 1.54 (0.96-2.39)
20-39 years 0.635 <0.0001b 1.89 (1.49-2.39)
40–59 yearsa
60–79 years −0.535 <0.0001b 0.59 (0.46-0.75)
≥ 80 years −1.399 <0.0001b 0.25 (0.14-0.41)
Acetaminophen
Reporting Year 0.023 0.1744 1.24 (0.89-1.73)
Gender female 0.287 0.0082b 1.33 (1.08-1.65)
Age
≤ 19 years 0.230 0.1292 1.26 (0.94-1.70)
20-39 years 0.266 0.0972 1.31 (0.95-1.79)
40–59 yearsa
60–79 years −0.184 0.2818 0.83 (0.60-1.16)
≥ 80 years −1.103 0.0004b 0.33 (0.16-0.62)
Carbamazepine
Reporting Year 0.005 0.7666 1.00 (0.97-1.04)
Gender female 0.187 0.0765 1.21 (0.98-1.48)
Age
≤ 19 years 0.083 0.6486 1.09 (0.76-1.55)
20-39 years 0.360 0.0209b 1.43 (1.06-1.95)
40–59 yearsa
Table 2 Adjusted reporting odds ratio of SJS/TEN stratified by
age (Continued)
60–79 years 0.416 0.0027b 1.52 (1.15-2.00)
≥80 years −0.419 0.1293 0.66 (0.36-1.12)
Lamotrigine
Reporting Year 0.036 0.3618 1.04 (0.96-1.12)
Gender female 0.158 0.1978 1.17 (0.92-1.49)
Age
≤ 19 years −0.992 <0.0001b 0.37 (0.22-0.60)
20-39 years −0.418 0.0034b 0.66 (0.50-0.87)
40–59 yearsa
60–79 years −0.176 0.2672 0.84 (0.61-1.14)
≥ 80 years 0.162 0.5984 1.18 (0.63-2.09)
aAs reference
bStatistically significant
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phenytoin, furosemide, angiotensin-converting enzyme
(ACE) inhibitors, and corticosteroids. Lamotrigine,
phenytoin and furosemide were evaluated in our pre-
vious report [9]. Furthermore, ACE inhibitors (i.e.,
imidapril hydrochloride, enalapril maleate, temocapril
hydrochloride, lisinopril hydrate, perindopril erbumine,
and alacepril) and corticosteroids (i.e., dexamethasone,
dexamethasone sodium phosphate, dexamethasone acet-
ate, triamcinolone acetonide, prednisolone, prednisolone
acetate, betamethasone, betamethasone/d-chlorphenir-
amine maleate mixture, betamethasone valerate/gentami-
cin sulfate, methylprednisolone, and methylprednisolone
sodium succinate), which were evaluated by Mockenhaupt
et al., were summarized [6].
The results of the time-to-onset analysis are sum-
marized in Table 3. The numbers of case reports for
allopurinol, loxoprofen, acetaminophen, carbamaze-
pine, lamotrigine, phenytoin, furosemide, ACE inhibi-
tors, and corticosteroids were 281, 340, 310, 270, 465,
117, 57, 47, and 89, respectively. Figure 1 shows a
histogram of the number of cases of SJS/TEN from
days 0 to 56. The median durations (interquartile
ranges) for SJS/TEN caused by allopurinol, loxoprofen,
acetaminophen, carbamazepine, lamotrigine, phenytoin,
furosemide, ACE inhibitors, and corticosteroids were 21
(12–35), 3 (1–8), 2 (1–5), 19 (12–33), 27 (14–37), 20
(11–29), 17 (9–45), 20 (6–33), and 19 (11–26) days,
respectively. More than half of the reports of SJS/
TEN onset following administration of loxoprofen and
acetaminophen were recorded within 4 days of the
initiation of treatment (Fig. 1). Furthermore, the scale
parameter α values of loxoprofen and acetaminophen
were 9.44 and 6.17, respectively. The upper 95 % CIs
of shape parameter β values for the drugs were all
less than 1, with the exceptions of those for carba-
mazepine, ACE inhibitors and corticosteroids.
Discussion
In this study, we evaluated the relationship between
aging and SJS/TEN using data from the JADER database.
We also applied time-to-onset analysis using WSP tests.
Our results provide important insights into the time-to-
onset for SJS/TEN using available data.
In the JADER database, the top five most frequently
administered drugs associated with SJS/TEN were allo-
purinol, loxoprofen, acetaminophen, carbamazepine, and
lamotrigine. These drugs are known as causal drugs for
SJS/TEN and are described in the Manual For Handling
Disorders Due to Adverse Drug Reactions published by
the Ministry of Health, Labour, and Welfare of Japan
(“Koseirodosho” in Japanese); therefore, we believe that
our results were reasonable. In contrast, in the FAERS
database, the top five most frequently administered
drugs associated with SJS/TEN were valdecoxib, lamotri-
gine, phenytoin, acetaminophen, and furosemide [9]. Be-
cause more than 70 % of reported cases from the U. S.
were included in the FAERS database, the differences in
prescriptions between Japan and the U. S. may explain
these differences.
To the best of our knowledge, few studies have exam-
ined SJS/TEN in the context of age-group stratification.
In this study, we examined the association between SJS/
TEN and drugs using age-stratified data obtained from
the JADER database. In a previous report, we described
the adjusted RORs, stratified by age, for the FAERS data-
base as follows: ≤17 years (2.87 [95 % CI, 2.67–3.07]),
18–39 years (1.46 [95 % CI, 1.37–1.55]), 40–59 years
(1.00 [as a reference]), 60–79 years (0.99 [95 % CI,
0.93–1.04]), and ≥80-years (1.06 [95 % CI, 0.97–1.16])
[9]. In the FAERS database, the adjusted RORs in the
youngest group (0–17 years) had the highest values of all
data and subset data for all drugs (valdecoxib, lamotrigine,
phenytoin, acetaminophen, and furosemide).













Scale parameter Shape parameter
α 95 % CI β 95 % CI
Allopurinol 281 21 12 35 0 1689 45.66 37.23 55.85 0.62 0.58 0.67
Loxoprofen 340 3 1 8 0 708 9.44 7.74 11.49 0.64 0.59 0.69
Acetaminophen 310 2 1 5 0 191 6.17 5.17 7.35 0.74 0.68 0.81
Carbamazepine 270 19 12 33 0 451 31.20 27.52 35.32 1.02 0.94 1.10
Lamotrigine 465 27 14 37 0 962 46.66 40.66 53.49 0.71 0.67 0.75
Phenytoin 117 20 11 29 1 1109 30.46 23.76 38.92 0.79 0.70 0.88
Furosemide 57 17 9 45 2 434 34.14 23.32 49.30 0.75 0.62 0.91
ACE inhibitorsa 47 20 6 33 0 227 38.02 25.62 55.48 0.81 0.65 1.00
Corticosteroidsb 89 19 11 26 0 206 25.01 20.56 30.30 1.17 1.00 1.35
aIt containd 6 drugs; imidapril hydrochloride, enalapril maleate, temocapril hydrochloride, lisinopril hydrate, perindopril erbumine, and alacepril
bIt containd 11 drugs; dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinolone acetonide, prednisolone, prednisolone acetate,
betamethasone, betamethasone/d-chlorpheniramine maleate mixture, betamethasone valerate/gentamicin sulfate, methylprednisolone, and methylprednisolone
sodium succinate
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Fig. 1 Histgram for time-to-onset profile of the SJS/TEN for the suspected drugs: (a) Allopurinol, (b) Loxoprofen, (c) Acetaminophen, (d)
Carbamazepine, (e) Lamotrigine, (f) Phenytoin, (g) Furosemide, (h) ACE inhibitors, and (i) Corticosteroids
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On the other hand, in the JADER database, the signal
in the 0–19- and 20–39-year-old groups (1.33 [95 % CI,
1.21–1.45] and 1.78 [95 % CI, 1.65–1.93], respectively)
was detected for the whole dataset (Table 2). The effects
of the term for stratified age were statistically significant
in all age groups. The adjusted RORs in the 0–19- and
20–39-year-old groups were higher than those in the
60–79- and ≥ 80-year-old groups. The ranges of the 95 %
CI for the 0–19- and 20–39-year-old-groups were not
overlapped with those for the 60–79- and ≥ 80-year-old-
groups. SJS/TEN is thought to be an immune-mediated
disease, and immune function decreases with age owing
to the reduced function of T lymphocytes [21]. Consist-
ent with these data and the results from our previous re-
ports with the FAERS database [9], one plausible reason
for this result may be differences in sensitivity to medi-
cation in younger versus older patients.
In addition to data mining approaches, data subsetting
is useful for the evaluation of adverse event association
in disproportionality analysis [22]. An intraclass ROR of
the subset can be calculated after subsetting from the
whole database [23]. The subset may be considered the
same therapeutic class, which consists of a population of
patients that presumably share a set of common risk
factors and diseases. This strategy helps to mitigate con-
founding and bias [24]. Therefore, in this study, we cal-
culated the adjusted ROR of the top five most frequently
administered drugs associated with SJS/TEN using the
subset analysis method. In the case of loxoprofen, the
likelihood ratio tests for the age terms of the 20–39-,
60–79-, and ≥ 80-year-old groups had statistically signifi-
cant effects. The adjusted RORs in the ≥ 80-year-old
group for loxoprofen, acetaminophen, and carbamaze-
pine were lowest among the stratified age groups. In our
study, the age group having the highest adjusted ROR
for each drug varied according to the drug. Genetic dif-
ferences in the human Leukocyte antigen (HLA) have
been reported as important factors contributing to the
onset of SJS/TEN or hypersensitivity to drugs [10, 25].
Further studies are needed to determine the mechanisms
through which these genetic factors explain our findings.
Accordingly, to evaluate the true risk of medications,
HLA genotyping should be evaluated in patients with
varying ethnic backgrounds in well-organized epidemio-
logical studies.
For acetaminophen, the adjusted RORs in patients in
the 0–19- and 20–39-year-old groups were higher than
those in the 60–79- and ≥ 80-year-old groups, although
these differences were not significant (the range of the
95 % CI for the 60–79-year-old group was overlapped
with those for the 0–19- and 20–39-year-old groups;
Table 2). This may be explained by the potential inclu-
sion of viral infection-induced SJS in data from the
JADER database, which were obtained using the terms
“SJS,” “oculomucocutaneous syndrome,” and “TEN.” SJS
can be induced by mycoplasma infection, which is com-
monly observed in younger patients, and the treatment
strategy for this condition would include antibiotics
and/or acetaminophen. The co-administration ratio with
antibiotics (63 antibiotics: cefcapene pivoxil hydrochloride
hydrate, clarithromycin, cefdinir, etc.) was 44.9 % (864/
1925) in the subset for acetaminophen; this was the high-
est value among the top five most frequently used drugs
(allopurinol: 9.8 % [258/2642], loxoprofen: 28.7 % [1352/
4714], carbamazepine: 6.0 % [272/4517], lamotrigine:
3.2 % [77/2375]). Therefore, the high incidence of SJS/
TEN in young patients may be explained by acetamino-
phen treatment.
In the EuroSCAR-study, Mockenhaupt et al. examined
the time course of SJS/TEN onset [6]. From their results
of the time latency between the beginning of drug use
and the onset of SJS/TEN, the time-to-onset duration of
acetaminophen was less than 4 days. In our study, the
median times-to-onset were 3 days for loxoprofen and
2 days for acetaminophen; these durations were rela-
tively short in comparison with those of other drugs. Be-
cause the scale parameter α values of loxoprofen and
acetaminophen were both less than 10, these small
values indicate that there was a narrow data distribution.
In the EuroSCAR Study, the median times-to-onset
(interquartile ranges) of allopurinol, carbamazepine,
phenytoin, and phenobarbital were 20 (14–32), 15 (12–20),
24 (16–33), and 17 (9–40) days, respectively. Our data for
these allopurinol, carbamazepine, and phenytoin were
similar to those in this previous study. Mockenhaupt et al.
categorized the relationship between SJS/TEN and their
examined drugs into three groups as follows: highly associ-
ated drugs (carbamazepine and nevirapine), nonassociated
drugs (ACE inhibitors and valproic acid), and drugs with
doubtful association (acetaminophen and corticosteroids)
[6]. In our study, acetaminophen was one of the top five
drugs associated with SJS/TEN. Therefore, patients receiv-
ing loxoprofen and acetaminophen treatment should be
closely monitored for symptoms of SJS/TEN within the
first 2–3 days of treatment in the Japanese population.
The time-to-onset analysis with the WSP method al-
lows detection of potential adverse events without re-
quiring a control population. In our study, we examined
the time-to-onset of SJS/TEN using the WSP test; the
results of the shape parameter β of the WSP indicated
that the risk of SJS/TEN after administration of allopur-
inol, loxoprofen, acetaminophen, lamotrigine, phenytoin,
and furosemide was decreased over time. In contrast,
the risk of SJS/TEN with carbamazepine, ACE inhibitors,
and corticosteroids remained almost constant. For corti-
costeroids, Mockenhaupt et al. speculated that the timing
of corticosteroid exposure was caused by accumulation of
cases during the same period as for associated drugs [6].
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Notably, less than 100 case reports involved furosemide,
ACE inhibitors, and corticosteroids; therefore, interpret-
ation of data from such small sample sizes should be per-
formed cautiously.
There are several limitations to this study, and the re-
sults obtained from SRSs, such as the JADER database,
should be interpreted with caution. SRS is passive
reporting system and is therefore subjected to many
biases, such as under-reporting, over-reporting, and con-
founders by comorbidities. Most notably, there is a lack
of comparison groups and missing data on patient char-
acteristics [16, 26]. Because of these limitations, the
crude RORs without logistic regression analysis do not
indicate the risk of adverse event occurrence in absolute
terms and can only offer a rough indication of signal
strength [16]. In this study, we partially refined the
results with a dedicated correction to detect possible
confounders present in the database, using logistic re-
gression and subset analysis. Despite this limitation, we
believe it may be acceptable to compare the adjusted
RORs of a particular adverse event derived from strati-
fied analysis within a particular context. We hope that
these data may enhance the information available to cli-
nicians and improve the management of SJS/TEN.
Conclusions
In summary, this study was the first to evaluate the associ-
ation between aging and SJS/TEN using the JADER data-
base and to apply the time-to-onset analysis technique to
SJS/TEN using the SRS. We demonstrated that the ad-
justed RORs in patients 39 years old or younger were rela-
tively high for the whole dataset and were particularly
high in patients who were administrated antipyretic anal-
gesics, such as loxoprofen or acetaminophen. More than
half of the cases of SJS/TEN onset following administra-
tion of loxoprofen and acetaminophen were observed
within 4 days. The median times-to-onset were 3 days for
loxoprofen and 2 days for acetaminophen. Thus, patients
receiving loxoprofen and acetaminophen treatment should
be closely monitored for symptoms of SJS/TEN within the
first 2–3 days of treatment in the Japanese population.
Our results are useful for improving the management of
SJS/TEN. Further research is needed in order to determine
the specific associations between drugs and SJS/TEN.
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